ArticleWorld journal of clinical pediatrics2025
Deficiency of anterior pituitary hormones in Noonan syndrome and its impact on response to growth hormone therapy.
Article in World journal of clinical pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Endocrine Phenotypes and Hormonal Treatment in Meier-Gorlin Syndrome: Report of Two Cases and a Systematic Review of Literature.Clinical endocrinology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNoonan syndrome (NS) is an autosomal dominant, multisystem disorder with a prevalence of 1 in 1000-2500. Multiple etiologies have been proposed for short stature in NS, including resistance to growth hormone (GH) and GH deficiency (GHD). Irrespective of the presence of GHD, NS is a Food and Drug Administration-approved indication for recombinant-GH therapy. Few case reports of combined anterior pituitary hormone deficiency (CPHD) in NS have been reported.
aimTo describe the clinico-biochemical characteristics of NS with CPHD and to assess the response to recombinant GH therapy.
methodsAn ambispective case-control study was conducted to compare the clinico-hormonal profile and response to recombinant-GH in pediatric patients with NS and CPHD and pediatric patients with NS but without CPHD.
resultsFive children with NS and CPHD were compared to 6 patients with NS but without CPHD. The most common anterior pituitary hormone involvement in combination with GHD was adrenocorticotrophic hormone deficiency causing hypocortisolemia (
conclusionHypoplasia of the pituitary and GHD with involvement of other pituitary hormones may be seen in NS and may determine response to recombinant GH therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.